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Abstract
To determine the efficacy and safety of adding ezetimibe to maximally tolerated lipid lowering
therapy in patients with HIV dyslipidemia.
Retrospective analysis of lipid parameters was conducted for 33 patients with HIV who had been
prescribed ezetimibe 10 mg per day.
Mean total cholesterol was reduced 21% (p < 0.001). Mean LDL was reduced 35% (p < 0.001).
Mean HDL increased 8% (p = 0.038). Mean triglyceride was reduced 34% (p = 0.006). Mean
Apolipoprotein B100 was reduced 33% (p = 0.043). No adverse events occurred.
Ezetimibe appears safe and effective in patients with HIV when added to maximally tolerated doses
of lipid lowering therapy.
Background
Patients with HIV have an increased risk of coronary artery
disease [1]. Part of this risk may be due to the hyperlipi-
demia associated with anti-retrovirals [1,2]. Often the
lipid goals of patients in this group are not achieved by the
therapy recommended in the current lipid lowering guide-
lines [3].
Ezetimibe which blocks the intestinal absorption of die-
tary cholesterol and bile acid absorption[4], has been
effective in optimizing lipid levels when added to tradi-
tional therapy in non-HIV positive patients [5,6]. In HIV
positive patients two studies have assessed the efficacy of
ezetimibe. Coll et al. showed that ezetimibe monotherapy
decreases LDL as effectively as fluvastatin monotherapy in
HIV positive patients [7]. Negredo et al. showed that LDL
was also reduced when ezetimibe was added to pravasta-
tin monotherapy[8].
It is not known if adding ezetimibe to maximally tolerated
lipid lowering therapy, whether it be a fibrate, a highly
potent statin or both, in HIV positive patients will further
optimize the serum lipid profile. Furthermore, the safety
profile of these combinations is not known in this popu-
lation.
33 HIV positive patients in our center were started on
ezetimibe, as they were not at target despite maximally
tolerated lipid lowering therapy. Serum lipid concentra-
tions before and after adding ezetimibe were analyzed to
assess its efficacy.
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Methods
We analysed the effect on the lipid profile of the addition
of ezetimibe in patients with HIV.
All patients were seen at the Immunodeficiency Clinic
(IDC)-HIV Metabolic Clinic at St. Paul's Hospital, Van-
couver, BC, Canada. This is a tertiary referral center where
over 700 patients receive care for HIV associated meta-
bolic disorders. Patients who were treated with Ezetimibe
during the time period January 2003 to May 2006 were
included. Ezetimibe was initiated only after they were on
the maximum tolerated doses of standard lipid lowering
therapy.
The effect of ezetimibe on the serum concentrations of
total cholesterol, LDL, HDL, triglycerides and apolipopro-
tein B were analysed. In addition, adverse events as
defined by an elevation in AST or ALT over 5 times ULN
or CK over 10 times normal or any symptom requiring
discontinuation were documented.
Ethics approval was granted by the Ethics Review Board at
St. Paul's Hospital.
Patients
40 patients seen in the IDC-HIV Metabolic Clinic had
been prescribed ezetimibe 10 mg per day orally. Seven of
these patients were not included (2 had alterations in
their other medications, 3 took ezetimibe for less than 4
weeks (discontinued due to reasons other than adverse
events such as the inability to pay for the medication),
and 2 had insufficient data).
Of the remaining 33 patients, 8 had type 2 diabetes melli-
tus, 16 had hypertension, 9 had prior vascular disease, 10
previously smoked and 3 of the patients were current
smokers. 31 of the patients were male and the average age
at the start of ezetimibe therapy was 51.4 years (range 39–
76).
24 of the patients were on HMG-CoA reductase inhibitors
(2 on pravastatin, 15 on rosuvastatin and 7 on atorvasta-
tin), 17 of the patients were on fibrates (all fenofibrate), 2
of the patients were on Niacin and 4 of the patients were
on salmon oil.
24 of the patients were taking protease inhibitors, 25 were
taking NNRTIs, 29 were taking NRTIs, 1 was taking T20
and 1 subject was on no anti-retroviral therapy.
The serum triglycerides were significantly elevated in 8 of
the patients precluding the calculation of serum LDL con-
centration. Only 7 of the patients had apolipoprotein B
measurements both before and after the institution of
ezetimibe.
Univariate analysis was used to compare the differences
between the pre and post treatment using the Wilcoxon
rank sum test for paired non-parametric samples. SPSS
version 14.0 was used to analyse the data.
Results
Mean total cholesterol was reduced from 6.95 mmol/L to
5.51 mmol/L (21% reduction, p < 0.001). Mean LDL was
reduced from 4.05 mmol/L to 2.63 mmol/L (35% reduc-
tion, p < 0.001). Mean HDL increased from 1.07 mmol/L
to 1.16 mmol/L (8% increase, p = 0.038). Mean triglycer-
ide was reduced from 6.22 mmol/L to 3.85 mmol/L (34%
reduction, p = 0.006). Mean apolipoprotein B100 was
reduced from 1.45 g/L to 1.09 g/L (33% reduction p =
0.043). The average duration of ezetimibe therapy was
79.6 days (range 33–193 days). No adverse events
occurred.
The patients were analyzed according to their baseline
lipid lowering therapy. The results are described in figure
1. When ezetimibe was added to maximally tolerated
doses of a statin and a fibrate, reductions were seen in
serum concentrations of total cholesterol (16%, p =
0.004), LDL (26%, p = 0.008), and triglycerides (28%, p =
0.021). Furthermore the serum HDL concentration
increased in this group (17%, p = 0.036). When ezetimibe
was added to maximally tolerated doses of statin mono-
therapy, reductions were also seen in serum concentra-
tions of total cholesterol (32%, p = 0.001), LDL (45%, p
= 0.008) and triglycerides (49%, p = 0.033) in the sub-
group of patients on maximally tolerated doses of statin
monotherapy. When ezetimibe was added to maximally
tolerated doses of fibrate monotherapy, the serum LDL
concentration decreased by 20% (p = 0.043). In each of
these subgroups, the concentrations of total cholesterol,
LDL, HDL, apolipoprotein B and triglycerides improved.
Due to small sample size only the results mentioned
above were statistically significant.
Conclusion
Following our analysis we conclude that adding ezetimibe
improves the lipid profile in patients with HIV on maxi-
mally tolerated doses of lipid lowering therapy.
In our group of 33 patients we found significant reduc-
tions in serum concentrations of total cholesterol, triglyc-
erides, LDL and apolipoprotein B100 following the
addition of ezetimibe. Serum concentrations of HDL also
rose significantly following this intervention. These gains
were achieved without any adverse events.
Our findings are concordant with studies which have
assessed the efficacy of ezetimibe in non-HIV populations
[5,6]. As one of the proposed mechanisms of dyslipi-
demia in patients with HIV is due to ARV therapy[9], weLipids in Health and Disease 2007, 6:15 http://www.lipidworld.com/content/6/1/15
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felt it was necessary to demonstrate the efficacy of
ezetimibe in this group.
Only two studies have described the use of ezetimibe in
patients with HIV. Coll et al compared ezetimibe mono-
therapy to fluvastatin monotherapy in 20 HIV positive
patients. Serum concentrations of LDL were reduced by
20% with ezetimibe monotherapy [7]. As our practice is
to add ezetimibe to other lipid lowering therapy, only 3
patients in our study were on ezetimibe monotherapy.
The serum LDL concentration was reduced by 32% in this
subgroup. This result was not statistically significant
owing to the small number of patients in this subgroup.
Negredo et al. added ezetimibe in 19 patients with HIV
who were not at target while on pravastatin. After 24
weeks of combination therapy of ezetimibe and pravasta-
tin, 61.5% of patients achieved an LDL less than 3.36
mmol/L (130 mg/dl). At baseline there were 14 patients
in our study on statin therapy who had a serum LDL con-
centration greater than 3.36 mmol/L. 9 of these patients
(64%) achieved an LDL of less than 3.36 mmol/L follow-
ing the addition of ezetimibe.
In our center, in the absence of consensus guidelines for
the treatment of dyslipidemia in patients with HIV, we
currently treat HIV positive patients to at least moderate
risk lipid profile targets (total cholesterol concentration of
less than or equal to 5.0 mmol/L, an LDL concentration of
less than or equal to 3.5 mmol/L and serum total choles-
terol to HDL ratio of less than or equal to 5.0). Prior to
ezetimibe therapy, none of the patients met all targets
despite maximally tolerated lipid lowering therapy (none
of the patients met the total cholesterol target, 6 of 25
patients met the LDL target and 4 of 33 patients met the
total cholesterol to HDL ratio target). Following the addi-
tion of ezetimibe the total cholesterol was reduced to less
than or equal to 5.0 mmol/L 13 of 33 patients (39%). The
LDL concentration was reduced to less than or equal to
3.5 mmol/L in 15 of 25 patients (60%). The ratio of total
cholesterol to HDL ratio was reduced to less than or equal
to 5.0 in 15 of 33 patients (45%). The results were then
analyzed according to baseline lipid lowering therapy.
Figure 2 describes which patients met moderate risk lipid
targets following the addition of ezetimibe despite not
meeting them at baseline.
The current published guidelines recommend diet and
exercise counseling, considering altering the ARV regimen
or adding lipid lowering medications for dyslipidemia in
patients on ARV therapy [3]. A statin is suggested for LDL
elevations and a fibrate is suggested for serum triglycerides
elevations. The current guidelines do not yet recommend
the use of ezetimibe therapy in this group.
Our study is the first to analyze the efficacy of adding
ezetimibe to maximally tolerated doses of the lipid lower-
ing therapy including highly potent statins, fibrates and
combinations of a statin and a fibrate. Significant
improvements in the lipid profile following the addition
of ezetimibe were seen. Furthermore, there were no
adverse events. We conclude that if the lipid targets are not
met after maximally tolerated doses of lipid lowering ther-
apy with a statin and/or fibrate, ezetimibe is safe and
effective.
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Ezetimibe add-on therapy: Percent of patients reaching tar- gets for moderate risk according to baseline lipid agent Figure 2
Ezetimibe add-on therapy: Percent of patients reaching tar-
gets for moderate risk according to baseline lipid agent.
Ezetimibe add-on therapy: Effect according to baseline lipid  agent * p < 0.05 Figure 1
Ezetimibe add-on therapy: Effect according to baseline lipid 
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